Reformulary Group and Aon Canada today announced a strategic alliance. Reformulary will be Aon’s partner in formulary design, and both parties will integrate its analytics into a powerful solution.
“Aon has a leading position in the health and benefits consulting space, as well as a significant client base reaching out for drug plan sustainability,” said Helen Stevenson, Founder & CEO of Reformulary Group. “We hope to use our combined expertise to bring solutions to Aon’s clients and help them to achieve better health and financial outcomes.” Reformulary Group brings specialist advice in the drug space, both related to employer-sponsored plans and provincially funded drug plans.
“More powerful, combined offerings”
The two companies plan to collaborate and leverage Aon and Reformulary’s respective data analytics capabilities “to provide even more powerful, combined offerings”. Earlier this year, Reformulary launched its Drug Early Warning (DEW) System to monitor the pipeline of new high-cost prescription drugs entering the Canadian marketplace and forecast the expected impact of these drugs on drug benefit plans.
Complicated drug environment
“By both firms working collaboratively, we are able to serve our clients in an evolving and complicated drug environment,” said Anthony Perlman, Senior Vice President and National Practice Leader, Aon Health and Benefits. “The output from this partnership will better assist plan sponsors in managing this aspect of the benefits programs.”
The non-exclusive strategic alliance allows each party to continue to collaborate with other firms and partners.